Summary: GSK plc

  • From a short-term investment perspective, the company presents a deteriorated fundamental situation
  • The company's Refinitiv ESG score, based on a ranking of the company relative to its industry, comes out particularly well.

Highlights: GSK plc

  • The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
  • The company returns high margins, thereby supporting business profitability.
  • The company is one of the best yield companies with high dividend expectations.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
  • Historically, the company has been releasing figures that are above expectations.

Weaknesses: GSK plc

  • In relation to the value of its tangible assets, the company's valuation appears relatively high.
  • For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
  • For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
  • The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.

Ratings Chart: GSK plc

surperformance-ratings-chart GSK-PLC
Source: Surperformance

ESG chart: GSK plc

esg-ratings-chart GSK-PLC
Source: Refinitiv

Add to a list
Composite Fundamentals Composite Valuation Composite Momentum Capi. ($)
70.69B
731B
475B
369B
301B
249B
240B
208B
200B
162B
Average 300.57B
Weighted average by Cap.
See all sector ratings
Investor Rating
Trading Rating
ESG Refinitiv
B

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Environment

Emissions
Innovation
Use of resources

Social

Social commitment
Human Rights
Product liability
Human Resources

Governance

CSR Strategy
Management
Shareholders

Controversy

Controversy

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes